Prolactin receptor–Janus kinase 2–signal transducer and activator of transcription 5 pathway (PRLR–JAK2–STAT5 pathway)

The prolactin receptor–JAK2–STAT5 pathway is a canonical cell signaling cascade activated by prolactin binding to its surface receptor (PRLR). Upon ligand engagement, PRLR dimerizes, which triggers activation of the associated cytoplasmic kinase JAK2. Activated JAK2 phosphorylates both the receptor and STAT5 (which exists as STAT5A and STAT5B isoforms); STAT5 then dimerizes and translocates to the nucleus, where it drives transcription of target genes involved in cell proliferation, survival, and tissue differentiation. The pathway is essential for mammary gland development and lactation, regulates metabolic and immune processes in other tissues, and is a critical growth and survival pathway in several cancers. Therapeutic interventions may target any of the key components (PRLR, JAK2, STAT5) to modulate pathway output in diseases such as cancer, inflammatory conditions, and proliferative disorders. The pathway has complex feedback controls and crosstalk with other signaling modules, such as PI3K/Akt and growth hormone pathways, complicating targeted modulation strategies.

Other names

PRL/JAK2/STAT5 pathwayProlactin receptor–JAK2–STAT5 axisPRLR–JAK2–STAT5 signaling cascadeJAK2–STAT5 signaling (when context is mammary, hematopoietic, or prolactin-driven)

Inhibition of JAK2 kinase activity (blocks phosphorylation of STAT5, suppresses downstream gene transcription). Antagonism of prolactin receptor (prevents pathway initiation). Inhibition of STAT5 dimerization or nuclear translocation (blocks transcriptional response). Disruption of receptor or kinase protein-protein interactions within the pathway complex.